Última actualización 12 de septiembre de 2026
Key finding
Fasting glucose decreased by -1.271 mmol/L compared to placebo.
HTD1801 demonstrated safety and potential metabolic benefits in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
HTD1801 demonstrated safety and potential metabolic benefits in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.
This research is significant as it highlights a potential new treatment option for patients suffering from type 2 diabetes and associated liver disease. The observed reductions in key metabolic markers could lead to improved management strategies for these patients, ultimately enhancing their quality of life and reducing the risk of complications.
Effectiveness of HTD1801 remains unclear due to lack of p-values. Study population may not be representative of all patients with type 2 diabetes. Limited long-term safety data available.
Published in
Publication details and source links for this paper.
Jiajia M, Hong Z, Min W, et al. HTD1801 is safe and demonstrates potential metabolic benefits in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Diabetology & Metabolic Syndrome. 2026;18:171. doi:10.1186/s13098-026-02202-3
Fasting plasma glucose decreased by -1.271 mmol/L compared to placebo.
LDL-C decreased by -0.623 mmol/L compared to placebo.
Total cholesterol decreased by -1.090 mmol/L compared to placebo.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to HTD1801 500 mg twice daily and 2-h postprandial glucose, Change in liver enzymes (GGT), Fasting Plasma Glucose (FPG), and 2 more.
This study contributes evidence to
Primary intervention
HTD1801 500 mg twice daily
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
5
Evidence pairs
886
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
HTD1801 500 mg twice daily → 2-h postprandial glucose
HTD1801 500 mg twice daily → 2-h postprandial glucose
HTD1801 500 mg twice daily → Change in liver enzymes (GGT)
HTD1801 500 mg twice daily → Change in liver enzymes (GGT)
HTD1801 500 mg twice daily → Fasting Plasma Glucose (FPG)
HTD1801 500 mg twice daily → Fasting Plasma Glucose (FPG)
HTD1801 500 mg twice daily → LDL cholesterol
HTD1801 500 mg twice daily → LDL cholesterol
HTD1801 500 mg twice daily → Total cholesterol
HTD1801 500 mg twice daily → Total cholesterol
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on HTD1801 500 mg twice daily and Fasting Glucose, HTD1801 500 mg twice daily and Adipokine and Angiogenic Markers.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies on HTD1801 500 mg twice daily
Contributes to HTD1801 500 mg twice daily evidence base.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
HTD1801 500 mg twice daily appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
HTD1801 500 mg twice daily appears to improve 2-h postprandial glucose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
2-h postprandial glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
HTD1801 500 mg twice daily appears to improve change in liver enzymes (GGT).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in liver enzymes (GGT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
HTD1801 500 mg twice daily appears to improve ldl cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
LDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
